Unknown

Dataset Information

0

Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients.


ABSTRACT: Raltegravir (RLT) prevents the integration of HIV DNA in the nucleus, but published studies remain controversial, suggesting that it does not decrease proviral DNA. However, there are only a few studies focused on virus-targeted cells. We aimed our study on the impact of RLT inclusion on total intra-cellular viral DNA (TID) in cellular subsets and immune effects in patients with newly acquired undetectable plasmatic viral load (UVL). Six patients having UVL using an antiretroviral combination for 6 months and CD4 T-cells > 350/mL and <500/mL were selected to receive RLT for 3 months from M0 to M3. Patients had 7 sequential viro-immunological determinations from M-1 to M5. Immune phenotypes were determined by flow cytometry and TID quantification was performed using PCR assay on purified cells. TID (median values) at the initiation of RLT in CD4 T-cells was 117 copies/millions of cells, decreased to 27.5 on M3, and remained thereafter permanently under the cut-off (<10 copies/millions of cells) in 4 out of 6 patients. This was associated with an increase of CD4 and CD4 + CD28+ T-cells and a decrease of HLA-DR expression and apoptosis of CD4 T-cells. RLT inclusion led to decreases in the viral load along with positive immune reconstitution, mainly for CD4 T-cells in HIV patients.

SUBMITTER: Kumar G 

PROVIDER: S-EPMC8773801 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5031918 | biostudies-literature
| S-EPMC58783 | biostudies-literature
| S-EPMC7221189 | biostudies-literature
| S-EPMC8212531 | biostudies-literature
| S-EPMC3316508 | biostudies-literature
| S-EPMC7417431 | biostudies-literature
| S-EPMC2621372 | biostudies-literature
| S-EPMC4198256 | biostudies-literature
| S-EPMC4768432 | biostudies-literature
| S-EPMC4780739 | biostudies-literature